| A Multicenter, Prospective, Observational, Non-Interventional Cohort Study Evaluating On-Treatment Predictors of Response in Subjects With HBeAg Positive and HBeAg Negative Chronic Hepatitis B Receiving Therapy With PEGASYS(R) (Peginterferon Alfa-2a 40KD) |
Completed |
Pegasys |
4 |
MV22009 |
King Fahad University Hospital (Al-Khobar), Armed Forces Hospital (Kharj) |
| A double blind, Double Dummy, Randomized, Multi-Centre study to assess the tolerability and Efficacy Profile of Vildagliptin Compared to Gliclazide as Dual Therapy with Metformin in Muslim Patients with Type 2 Diabetes Fasting During Ramadan. |
Completed |
Vildagliptin /Gliclazide / Metformin |
4 |
CLAF237A2411 |
King Fahad University Hospital (Al-Khobar)_ King Abdulaziz Medical City NG (Riyadh) |
| UNraveling nAMD real life Clinical management and Outcome with intraVitrEal Ranibizumab injection – A retrospective analysis (UNCOVER) |
Completed |
Ranibizumab |
4 |
CRFB0021 |
King Khaled Eye Specialist Hospital (Riyadh) |
| Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma |
Completed |
Bevacizumab |
3 |
MO22923 |
King Fahad Medical City (Riyadh)_ King Fahad Specialist Hospital (Dammam) |
| A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovascular Risk |
Completed |
BI 10773 |
3 |
1245.25 |
King Fahad Medical City (Riyadh) |
| Phase 2, Single-Site, Open-Label, Randomized, 2-ArmParallel Study to Assess the Efficacy and Safety ofRyanodex® (EGL-4104) as Adjuvant Treatment inSubjects With Exertional Heat Stroke (EHS |
Completed |
Dantrolene |
2 |
EGL-4104-C-1502 |
King Fahad Medical City (Riyadh) |
| A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Sitagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes |
Completed |
ITCA 650 |
3 |
ITCA 650-CLP-105 |
King Abdulaziz Medical City NG (Jeddah)_ King Abdulaziz Hospital NG (Al Ahsa)_ Imam Abdulrahman Al Faisal Hospital NG (Dammam)_ King Fahad Medical City (Riyadh) |
| An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 (Sebelipase Alfa) in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency |
Completed |
Sebelipase alfa (SBC-102) |
2 |
LAL-CL03 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| "Phase 3, Open/Label Study to evaluate the safety and efficacy of TMC 435 plus Pegylated Interferon alfa-2a and Ripavirin administrated for 12 weeks in treatment-naïve Subjects with Chronic genotype 1 or genotype 4 HCV infection" |
Completed |
TMC435 (simeprevir) / Pegylated interferon alfa-2a (PegIFNα-2a) / Ribavirin (RBV) |
3b |
TMC435HPC3014 |
King Faisal Specialist Hospital and Research Center (Riyadh)_ King Abdulaziz Medical City NG (Riyadh)_ King Khalid University Hospital (Riyadh) |
| A 3 Month, Multicenter, Double-Masked Safety and Efficacy Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients |
Completed |
Travoprost 0.004% / Timolol |
3 |
C-12-008 |
King Khaled Eye Specialist Hospital (Riyadh) |
